本瑞利珠单抗治疗2年可使重度嗜酸性哮喘持续缓解
这项多中心观察性研究纳入164例重度嗜酸性哮喘患者,评估本瑞利珠单抗治疗2年的 sustained remission(持续缓解)。24个月后42.1%(69例)达到持续缓解,合并鼻息肉者中40.2%鼻息肉持续改善;合并鼻息肉与支气管舒张后气流受限可逆是持续缓解的独立预测因素。
要点
- 本瑞利珠单抗治疗24个月后42.1%的重度嗜酸性哮喘患者达到持续缓解。
- 合并慢性鼻窦炎伴鼻息肉者中40.2%鼻息肉持续改善。
- 合并鼻息肉与气流受限可逆性提示更易获得持续缓解。
核心结论
- 本瑞利珠单抗可在真实临床中诱导重度嗜酸性哮喘的持续缓解,合并慢性鼻窦炎伴鼻息肉及气流受限可逆者更易获益。
研究设计与样本
- 多中心观察性研究,纳入164例重度嗜酸性哮喘患者,接受本瑞利珠单抗附加治疗并随访2年。
- 持续缓解采用四组分评估:哮喘急性发作、口服糖皮质激素使用、症状控制与肺功能。
主要发现
- 治疗24个月后69例(42.1%)达到持续缓解,即急性发作率=0、口服糖皮质激素剂量=0、支气管舒张前FEV1≥80%预计值、ACT评分≥20。
- 82例合并鼻息肉患者中33例(40.2%)鼻息肉持续改善,即SNOT-22<30、鼻息肉复发=0。
- 合并鼻息肉(OR=2.32,p<0.05)与支气管舒张后气流受限可逆(OR=5.59,p<0.01)是持续缓解的独立预测因素。
关键数值与推荐
- 持续缓解定义:急性发作率=0、口服糖皮质激素剂量=0、支气管舒张前FEV1≥80%预计值、ACT评分≥20。
- 鼻息肉持续改善定义:SNOT-22<30、鼻息肉复发=0。
- 合并鼻息肉OR=2.32(p<0.05),支气管舒张后气流受限可逆OR=5.59(p<0.01)。
临床怎么用
- 对重度嗜酸性哮喘患者,本瑞利珠单抗治疗2年可使部分患者达到无急性发作、停用口服激素且肺功能与症状控制良好的持续缓解。
- 合并慢性鼻窦炎伴鼻息肉或气流受限可逆者,可优先考虑本瑞利珠单抗并预期更高持续缓解可能。
局限性
- 为观察性研究,非随机对照,持续缓解的因果推断受限。
- 原文摘要未报告安全性数据、样本量细节以外的统计信息及随访更长时限的结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Several randomized controlled trials (RCTs) have shown that benralizumab is characterized by a good profile of efficacy and safety, thereby being potentially able to elicit clinical remission on-treatment of severe eosinophilic asthma (SEA). The main goal of this multicentre observational study was to verify the effectiveness of benralizumab in inducing a sustained remission on-treatment of SEA in patients with or without comorbid chronic rhinosinusitis with nasal polyps (CRSwNP). METHODS: Throughout 2 years of treatment with benralizumab, a four-component evaluation of sustained remission of SEA was performed, including the assessment of SEA exacerbations, use of oral corticosteroids (OCSs), symptom control and lung function. RESULTS: The present study recruited 164 patients suffering from SEA. After 24 months of add-on biological therapy with benralizumab, 69 (42.1%) achieved the important target of sustained remission on-treatment (exacerbation rate = 0, OCS dose = 0, pre-bronchodilator FEV1 ≥80% pred., ACT score ≥ 20). During the same period, a persistent improvement of CRSwNP (SNOT-22 < 30, NP recurrence = 0) was observed in 33 (40.2%) out of 82 subjects with concomitant NP. The latter comorbidity and post-bronchodilator reversibility of airflow limitation were two independent predictors of sustained remission on-treatment (OR = 2.32, p < 0.05 and OR = 5.59, p < 0.01, respectively). CONCLUSION: Taken together, the results of this real-life clinical investigation indicate that benralizumab can induce a sustained remission on-treatment of SEA, especially in those patients with comorbid CRSwNP and reversible airflow limitation.
引用
- Pelaia, Crimi, Benfante, et al. Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis. Respirology. 2024. PMID: 38847185. doi:10.1111/resp.14767
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。